CD69

CD69 Overview

English Name	Early activation antigen CD69	Approved Drugs	0
Drugs in Clinical Trials	0	Target Synonym
Highest Development Stage	Preclinical

English Name	Early activation antigen CD69
Target Synonym
Approved Drugs	0
Drugs in Clinical Trials	0
Highest Development Stage	Preclinical

CD69 Product List

Product Category
Protein (1)Antibody (1)
Product Status
Launched (2)
Species
Human (1)Mouse (1)
Tag
His Tag (1)- (1)
Conjugate
Unconjugated (1)PE Labeled (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature	Order Now
CD9-H5222	Human	HEK293	Human CD69 / CLEC2C Protein, His Tag				Add to Cart
FABm022-01	Mouse	Hybridoma	PE-Labeled Monoclonal Anti-Human CD69 Antibody, Mouse IgG1 (3C5B7) (0.03% Proclin)				Add to Cart

Total: 2

CD69 Background

Early activation antigen CD69 is also known as C-type lectin domain family 2 member C (CLEC2C), Activation inducer molecule (AIM), Early T-cell activation antigen p60, Leukocyte surface antigen Leu-23. CD69 contains one C-type lectin domain. CD69 / CLEC2C is expressed on the surface of activated T-cells, B-cells, natural killer cells, neutrophils, eosinophils, epidermal Langerhans cells and platelets. CD69 is induced by antigens, mitogens or activators of PKC on the surface of T and B-lymphocytes and by interaction of IL-2 with the p75 IL-2R on the surface of NK cells. CD69 / CLEC2C involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets.